Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.

Published in: Therapeutic drug monitoring (2024)

Using neonatal saliva for buprenorphine therapeutic drug monitoring can facilitate newborn safety during the maternal treatment of OUD using sublingual buprenorphine. Nevertheless, the suitability of using adult values of respiratory depression EC50 for newborns must be confirmed.

Keyphrases

birth weight
pregnancy outcomes
gestational age
allergic rhinitis
low birth weight
pregnant women
depressive symptoms
sleep quality
young adults
cord blood
replacement therapy
childhood cancer